Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 5/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | QSOX1 | O00391 | 1/20 | 0.51 |
| ▸ | RGS12 | O14924 | 1/20 | 0.51 |
| ▸ | PMM2 | O15305 | 1/20 | 0.51 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.51 |
| ▸ | GMNN | O75496 | 1/20 | 0.51 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYBB | P04839 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5916901 | 0.82 | METAP2 (0.54) | METAP2HDAC6KDM4EMEN1QSOX1 | |
| SCHEMBL30573263 | 0.82 | METAP2 (0.51) | METAP2HDAC6KDM4EMEN1QSOX1 | |
| SCHEMBL10958968 | 0.82 | METAP2 (0.51) | METAP2HDAC6KDM4EMEN1QSOX1 | |
| SCHEMBL5916583 | 0.79 | METAP2 (0.54) | METAP2HDAC6KDM4EMEN1QSOX1 | |
| SCHEMBL5916849 | 0.78 | LMNA (0.48) | METAP2HDAC6KDM4EMEN1QSOX1 | |
| SCHEMBL5916782 | 0.78 | METAP2 (0.61) | METAP2HDAC6KDM4EMEN1QSOX1 | |
| SCHEMBL10956173 | 0.77 | METAP2 (0.53) | METAP2HDAC6KDM4EMEN1QSOX1 | |
| SCHEMBL10599445 | 0.76 | METAP2 (1.00) | METAP2HDAC6KDM4EMEN1QSOX1 | |
| SCHEMBL28615461 | 0.76 | METAP2 (0.57) | METAP2HDAC6KDM4EMEN1QSOX1 | |
| SCHEMBL29864488 | 0.76 | METAP2 (0.44) | METAP2HDAC6KDM4EMEN1QSOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135569-A1 | Use of benzisoselenazolone compounds against ischemic myocardial damage | INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2006-06-22 | — | — | US | claimed |
| EP-1541145-A1 | THE USE OF BENZISOSELENAZOLONE COMPOUNDS AGAINST ISCHEMIC MYOCARDIAL DAMAGE | Institute of Materia, Chinese Academy of Medical Sciences (CN) | 2005-06-15 | — | — | EP | claimed |
| US-20190142801-A1 | USE OF SMALL MOLECULES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE TOXICITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2019-05-16 | — | — | US | disclosed |
| US-10172829-B2 | Use of small molecules for the treatment of clostridium difficile toxicity | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-01-08 | — | — | US | disclosed |
| US-20170128420-A1 | USE OF SMALL MOLECULES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE TOXICITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2017-05-11 | — | — | US | disclosed |
| US-20060135569-A1 | Use of benzisoselenazolone compounds against ischemic myocardial damage | INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2006-06-22 | — | — | US | disclosed |
| EP-1541145-A1 | THE USE OF BENZISOSELENAZOLONE COMPOUNDS AGAINST ISCHEMIC MYOCARDIAL DAMAGE | Institute of Materia, Chinese Academy of Medical Sciences (CN) | 2005-06-15 | — | — | EP | disclosed |
| EP-0257306-B1 | DISELENOBIS BENZOIC ACID AMIDES OF PRIMARY HETEROCYCLIC AMINES, PROCESS FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOUNDS COMPRISING THE SAME | A. Nattermann & Cie. GmbH (DE) | 1990-09-12 | — | — | EP | disclosed |
| US-4910313-A | Containing a heterocyclic ring | NATTERMANN & CIE GMBH (DE) | 1990-03-20 | — | — | US | disclosed |
| EP-0100899-B1 | BENZISOSELENAZOLONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | A. Nattermann & Cie. GmbH (DE) | 1988-06-15 | — | — | EP | disclosed |
| EP-0257306-A1 | Diselenobis benzoic acid amides of primary heterocyclic amines, process for producing the same and pharmaceutical compounds comprising the same | A. Nattermann & Cie. GmbH (DE) | 1988-03-02 | — | — | EP | disclosed |
| US-4550168-A | Benzisoselenazolones and a process for the treatment of inflammatory diseases | A. NATTERMANN & CIE GMBH (DE) | 1985-10-29 | — | — | US | disclosed |
| EP-0100899-A2 | Benzisoselenazolones, process for their preparation and pharmaceutical compositions containing them | A. Nattermann & Cie. GmbH (DE) | 1984-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172829-B2 | Use of small molecules for the treatment of clostridium difficile toxicity | SLC10A2, TCERG1, SBDS | METAP2 1571/4885HDAC6 246/4885KDM4E 2185/4885 |
| US-20190142801-A1 | USE OF SMALL MOLECULES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE TOXICITY | SLC10A2, TCERG1, SBDS | METAP2 1571/4885HDAC6 246/4885KDM4E 2185/4885 |
| US-20170128420-A1 | USE OF SMALL MOLECULES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE TOXICITY | SLC10A2, TCERG1, SBDS | METAP2 1571/4885HDAC6 246/4885KDM4E 2185/4885 |
| US-20060135569-A1 | Use of benzisoselenazolone compounds against ischemic myocardial damage | TNNI3, TNNT2, MYLK2 | METAP2 4321/4885HDAC6 801/4885KDM4E 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.